Monitra Health Secures US Patent for Advanced Wireless Cardiac Monitoring Device

The patent, titled Wireless Cardiac Monitoring Device and Method to Measure and Transmit Cardiac Physiological Signals, was issued by the United States Patent and Trademark Office on October 8, 2024.

Monitra Health, a healthcare technology provider, has been granted US Patent for its wireless cardiac monitoring technology.

The patent, titled Wireless Cardiac Monitoring Device and Method to Measure and Transmit Cardiac Physiological Signals, was issued by the United States Patent and Trademark Office on October 8, 2024.

The patented innovation introduces a patch-based wireless cardiac monitoring device to improve diagnostic precision and patient adherence. Designed for ambulatory ECG monitoring, the device detects conditions such as atrial fibrillation, cardiac arrhythmias, and QT prolongation, particularly during clinical trials.

Key Features of the Device

The wireless cardiac monitoring patch integrates advanced technology to ensure seamless data collection and transmission. It can detect its orientation on the patient’s body and automatically select the most effective electrode pairs to maintain high signal quality. This reduces errors caused by improper placement and enhances diagnostic reliability.

The device processes bio-potential signals in real-time, transmitting data wirelessly to external systems for further analysis. This connectivity supports efficient ECG and physiological data monitoring, enabling prompt clinical decision-making.

Applications in Cardiac Monitoring

Monitra Health's patented technology has significant implications for healthcare, particularly in outpatient settings. The wireless patch is designed to aid in ambulatory ECG monitoring, offering precise diagnostics for conditions that require continuous monitoring. It also plays a critical role in clinical trials, assisting in QT prolongation monitoring to ensure cardiac safety during drug development.

The company plans to commercialise the technology and expand its market presence in the United States, the United Kingdom, and Australia.

Monitra Health has not disclosed specific timelines for the commercial rollout but emphasised its commitment to advancing cardiac care through innovation and global market expansion.